Table 2 Association between demographic and clinical factors with M. tuberculosis genotypes clustering

Variable

Level

Unclustered, n = 13 (%)

Clustered, n = 57 (%)

P-value

Odds ratio (95% CI)

Sex

Female

6 (46%)

22 (39%)

0.789

Referent

Male

7 (54%)

35 (61%)

1.36 (0.41–4.49)

Age groups

Adults

(> 17 y)

12 (92%)

53 (93%)

1.000

Referent

Children

= < 16 y

1 (8%)

4 (7%)

0.91 (0.09–8.85)

TB/DOTS Facilities

Folang

0

1 (2%)

0.735

1--

Kalafong

5 (38%)

21 (37%)

0.53 (0.05–5.21)

Mamelodi

1 (8%)

9 (7%)

1.13 (0.06–21.08)

Potchefstroom

0

4 (7%)

1--

Pretoria West

1 (8%)

3 (5%)

0.38 (0.02–8.10)

Skinner

1 (8%)

1 (2%)

0.13 (0–4.00)

Steve Biko

4 (31%)

10 (18%)

0.31 (0.03–3.38)

Tshwane

1 (8%)

8 (14%)

Referent

Any drug resistance

Susceptible

10 (77%)

49 (86%)

0.416

Referent

Resistance

3 (23%)

8 (14%)

0.54 (0.12–2.42)

INH mono-resistance

Susceptible

13 (100%)

52 (91%)

0.576

1--

Resistance

0

5 (9%)

MDR/RIF*

Susceptible

10 (77%)

49 (91%)

0.179

Referent

Resistance

3 (23%)

5 (9%)

0.34 (0.07–1.66)

Disease site

Disseminated

1 (8%)

3 (5%)

0.540

Referent

Lymph nodes

4 (31%)

16 (28%)

1.33 (0.11–16.48)

Meninges

1 (8%)

4 (7%)

1.33 (0.06–31.12)

EPTB/PTB

1 (8%)

2 (4%)

0.67 (0.02–18.06)

Pericardium

0

1 (2%)

1--

Peritoneum

0

5 (9%)

1--

Pleura

2 (15%)

18 (32%)

3 (0.20–44.36)

Genitourinary

0

2 (4%)

1--

Cutaneous TB

4 (31%)

6 (11%)

0.5 (0.04–6.68)

Beijing Clade

Yes

0

25 (44%)

0.003

--1

No

13 (100%)

32 (56%)

Euro-American

No

12 (92%)

31 (54%)

0.011

Yes

1 (8%)

26 (46%)

10.06 (1.23–82.64)

East-Africa-India

No

13 (100)

51 (89)

0.221

Yes

0

6 (11%)

--1